Regeneron's Dupixent fuels growth amid Eylea challenges.

Regeneron Pharmaceuticals reported a significant 17% year-over-year revenue increase, reaching $4.3 billion in the second quarter. This growth was primarily fueled by Dupixent, a collaborative drug with Sanofi, which saw its global sales jump 38% to $6 billion. Dupixent's expanding approvals for conditions like COPD and asthma have made it a key growth driver for Regeneron, helping to offset challenges faced by its Eylea eye medication.

Despite a 12% year-over-year decline in combined U.S. sales for both Eylea formulations, Regeneron's overall performance was robust. The company is actively pursuing strategies to ensure long-term success, including developing new formulations of Dupixent to maintain market share beyond its patent life. Furthermore, Regeneron is advancing its pipeline, notably with olatorepatide, an investigational weight-loss drug that demonstrated substantial results in a Chinese Phase 3 study, offering potential in the rapidly growing weight-loss market.